Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Neuroblastoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

mogamulizumab 4Specimen Handling 3Immunoglobulin G 3Disulfides 3Cyclophosphamide 3Biopsy 3pembrolizumab 2fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Photopheresis 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Magnetic Resonance Spectroscopy 2Busulfan 2Blood Specimen Collection 2talimogene laherparepvec 1magrolimab 1duvelisib 1durvalumab 1Vincristine 1Valganciclovir 1Urine Specimen Collection 1Transplantation 1Therapeutics 1Sirolimus 1Radiotherapy 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sezary Syndrome × Fenretinide × 1 year × Clear all
NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡